

Giulia Chiesa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/264461/publications.pdf>

Version: 2024-02-01

76
papers

3,680
citations

172207

29
h-index

128067

60
g-index

81
all docs

81
docs citations

81
times ranked

3328
citing authors

#	ARTICLE	IF	CITATIONS
1	Lack of ApoA-I in ApoEKO Mice Causes Skin Xanthomas, Worsening of Inflammation, and Increased Coronary Atherosclerosis in the Absence of Hyperlipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 839-856.	1.1	6
2	Aortic Gene Expression Profiles Show How ApoA-I Levels Modulate Inflammation, Lysosomal Activity, and Sphingolipid Metabolism in Murine Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 651-667.	1.1	12
3	Rupatadine treatment is associated to atherosclerosis worsening and altered T lymphocyte recruitment. <i>Thrombosis and Haemostasis</i> , 2021, 0, .	1.8	0
4	reString: an open-source Python software to perform automatic functional enrichment retrieval, results aggregation and data visualization. <i>Scientific Reports</i> , 2021, 11, 23458.	1.6	6
5	Fenretinide treatment accelerates atherosclerosis development in apoE-deficient mice in spite of beneficial metabolic effects. <i>British Journal of Pharmacology</i> , 2020, 177, 328-345.	2.7	21
6	Myocardial overexpression of ANKRD1 causes sinus venosus defects and progressive diastolic dysfunction. <i>Cardiovascular Research</i> , 2020, 116, 1458-1472.	1.8	15
7	The Gut Microbiota Affects Host Pathophysiology as an Endocrine Organ: A Focus on Cardiovascular Disease. <i>Nutrients</i> , 2020, 12, 79.	1.7	52
8	liputils: a Python module to manage individual fatty acid moieties from complex lipids. <i>Scientific Reports</i> , 2020, 10, 13368.	1.6	3
9	Fat-Shaped Microbiota Affects Lipid Metabolism, Liver Steatosis, and Intestinal Homeostasis in Mice Fed a Low-Protein Diet. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e1900835.	1.5	11
10	Infusions of Large Synthetic HDL Containing Trimeric apoA-I Stabilize Atherosclerotic Plaques in Hypercholesterolemic Rabbits. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1400-1408.	0.8	11
11	Topiramate protects apoE-deficient mice from kidney damage without affecting plasma lipids. <i>Pharmacological Research</i> , 2019, 141, 189-200.	3.1	21
12	Lipid phosphate phosphatase 3 in vascular pathophysiology. <i>Atherosclerosis</i> , 2018, 271, 156-165.	0.4	25
13	Effects of Vegetable Proteins on Hypercholesterolemia and Gut Microbiota Modulation. <i>Nutrients</i> , 2018, 10, 1249.	1.7	26
14	Liver-specific deletion of the Ppp3 gene alters plasma lipid composition and worsens atherosclerosis in apoE ^{-/-} mice. <i>Scientific Reports</i> , 2017, 7, 44503.	1.6	37
15	Effect of Dietary Components from Antarctic Krill on Atherosclerosis in apoE-deficient Mice. <i>Molecular Nutrition and Food Research</i> , 2017, 61, 1700098.	1.5	40
16	L-homoarginine administration reduces neointimal hyperplasia in balloon-injured rat carotids. <i>Thrombosis and Haemostasis</i> , 2016, 116, 400-402.	1.8	22
17	Nutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk Reduction. <i>Marine Drugs</i> , 2016, 14, 113.	2.2	36
18	High-Density Lipoprotein-Targeted Therapy and Apolipoprotein A-I Mimetic Peptides. <i>Circulation Journal</i> , 2015, 79, 2523-2528.	0.7	23

#	ARTICLE	IF	CITATIONS
19	High-density lipoprotein deficiency in genetically modified mice deeply affects skin morphology: A structural and ultrastructural study. <i>Experimental Cell Research</i> , 2015, 338, 105-112.	1.2	17
20	Magnetic Resonance Imaging Visualization of Vulnerable Atherosclerotic Plaques at the Brachiocephalic Artery of Apolipoprotein E Knockout Mice by the Blood-Pool Contrast Agent B22956/1. <i>Molecular Imaging</i> , 2014, 13, 7290.2014.00012.	0.7	16
21	A Salmon Protein Hydrolysate Exerts Lipid-Independent Anti-Atherosclerotic Activity in ApoE-Deficient Mice. <i>PLoS ONE</i> , 2014, 9, e97598.	1.1	40
22	Prevalence of classical CD14 ⁺⁺ /CD16 ⁺ but not of intermediate CD14 ⁺⁺ /CD16 ⁺ monocytes in hypoalphalipoproteinemia. <i>International Journal of Cardiology</i> , 2013, 168, 2886-2889.	0.8	15
23	Effect of the combinations between pea proteins and soluble fibres on cholesterolaemia and cholesterol metabolism in rats. <i>British Journal of Nutrition</i> , 2013, 110, 1394-1401.	1.2	28
24	An Immunomodulating Fatty Acid Analogue Targeting Mitochondria Exerts Anti-Atherosclerotic Effect beyond Plasma Cholesterol-Lowering Activity in apoE ^{-/-} Mice. <i>PLoS ONE</i> , 2013, 8, e81963.	1.1	17
25	Reduced biliary sterol output with no change in total faecal excretion in mice expressing a human apolipoprotein A-II variant. <i>Liver International</i> , 2012, 32, 1363-1371.	1.9	17
26	Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1246-1248.	1.8	18
27	Cholesterol-lowering effect of dietary <i>Lupinus angustifolius</i> proteins in adult rats through regulation of genes involved in cholesterol homeostasis. <i>Food Chemistry</i> , 2012, 132, 1475-1479.	4.2	29
28	The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: A possible impact on the natural history of the disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 87-93.	1.8	22
29	Rosuvastatin does not affect human apolipoprotein A-I expression in genetically modified mice: a clue to the disputed effect of statins on HDL. <i>British Journal of Pharmacology</i> , 2011, 164, 1460-1468.	2.7	22
30	Hypolipidemic effect of dietary pea proteins: Impact on genes regulating hepatic lipid metabolism. <i>Molecular Nutrition and Food Research</i> , 2010, 54, S24-30.	1.5	44
31	Intracellular ANKRD1 protein levels are regulated by 26S proteasome-mediated degradation. <i>FEBS Letters</i> , 2009, 583, 2486-2492.	1.3	22
32	HDL Therapy for the Treatment of Cardiovascular Diseases. <i>Current Vascular Pharmacology</i> , 2009, 7, 550-556.	0.8	20
33	Reduced mammary tumor progression in a transgenic mouse model fed an isoflavone-poor soy protein concentrate. <i>Molecular Nutrition and Food Research</i> , 2008, 52, 1121-1129.	1.5	9
34	Transcriptional deregulation and a missense mutation define ANKRD1 as a candidate gene for total anomalous pulmonary venous return. <i>Human Mutation</i> , 2008, 29, 468-474.	1.1	52
35	Dose-Related Effects of Repeated ETC-216 (Recombinant Apolipoprotein A-I-Milano/1-Palmitoyl-2-Oleoyl) Tj ETQq1 1 0.784314 rgBT /Ove American College of Cardiology, 2008, 51, 1098-1103.	1.2	87
36	Hypolipidaemic and anti-atherosclerotic effects of lupin proteins in a rabbit model. <i>British Journal of Nutrition</i> , 2008, 100, 707-710.	1.2	61

#	ARTICLE	IF	CITATIONS
37	Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 925-931.	1.1	137
38	Acute effects of high-density lipoproteins: biochemical basis and clinical findings. <i>Current Opinion in Cardiology</i> , 2008, 23, 379-385.	0.8	22
39	Th-P15:199 Modulation of pentraxin 3 expression in endothelial cells: Role of HDL. <i>Atherosclerosis Supplements</i> , 2006, 7, 537.	1.2	0
40	Tu-W23:7 Effect of high cholesterol diet on cholesterol and bile acid metabolism in A-IM and A-I transgenic mice. <i>Atherosclerosis Supplements</i> , 2006, 7, 167.	1.2	0
41	We-P14:483 Evaluation of nutritional and biological properties of a lupin protein isolate in Sprague-Dawley rats. <i>Atherosclerosis Supplements</i> , 2006, 7, 453-454.	1.2	0
42	Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. <i>British Journal of Pharmacology</i> , 2006, 149, 909-919.	2.7	50
43	Lupin (<i>Lupinus albus</i>) Protein Isolate (L-ISO) Has Adequate Nutritional Value and Reduces Large Intestinal Weight in Rats after Restricted and ad libitum Feeding. <i>Annals of Nutrition and Metabolism</i> , 2006, 50, 528-537.	1.0	18
44	Reference maps of mouse serum acute-phase proteins: Changes with LPS-induced inflammation and apolipoprotein A-I and A-II transgenes. <i>Proteomics</i> , 2005, 5, 4245-4253.	1.3	53
45	A simple method for the characterization and quantification of soy isoflavone metabolites in the serum of MMTV-Neu mice using high-performance liquid chromatography/electrospray ionization mass spectrometry with multiple reaction monitoring. <i>Rapid Communications in Mass Spectrometry</i> , 2005, 19, 153-161.	0.7	15
46	High-Density Lipoproteins Induce Transforming Growth Factor- β 2 Expression in Endothelial Cells. <i>Circulation</i> , 2005, 111, 2805-2811.	1.6	84
47	Apolipoprotein A-I and the molecular variant apoA-IMilano: Evaluation of the antiatherogenic effects in knock-in mouse model. <i>Atherosclerosis</i> , 2005, 183, 222-229.	0.4	42
48	Evaluation of a soft atherosclerotic lesion in the rabbit aorta by an invasive IVUS method versus a non-invasive MRI technology. <i>Atherosclerosis</i> , 2004, 174, 25-33.	0.4	21
49	Soy proteins reduce progression of a focal lesion and lipoprotein oxidizability in rabbits fed a cholesterol-rich diet. <i>Atherosclerosis</i> , 2003, 171, 163-170.	0.4	25
50	Recombinant apolipoprotein A-I [Formula: See Text]: a novel agent for the induction of regression of atherosclerotic plaques. <i>Annals of Medicine</i> , 2003, 35, 267-273.	1.5	24
51	Targeted Replacement of Mouse Apolipoprotein A-I with Human ApoA-I or the Mutant ApoA-IMilano. <i>Journal of Biological Chemistry</i> , 2003, 278, 4740-4746.	1.6	30
52	Apolipoprotein A-IMilano: current perspectives. <i>Current Opinion in Lipidology</i> , 2003, 14, 159-163.	1.2	85
53	Recombinant Apolipoprotein A-IMilano Infusion Into Rabbit Carotid Artery Rapidly Removes Lipid From Fatty Streaks. <i>Circulation Research</i> , 2002, 90, 974-980.	2.0	192
54	Mast Cell Chymase Degrades ApoE and ApoA-II in ApoA-I Knockout Mouse Plasma and Reduces Its Ability to Promote Cellular Cholesterol Efflux. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1475-1481.	1.1	53

#	ARTICLE	IF	CITATIONS
55	Omega-3 fatty acid ethyl esters increase heart rate variability in patients with coronary disease. <i>Pharmacological Research</i> , 2002, 45, 475-478.	3.1	70
56	Use of recombinant apolipoproteins in vascular diseases: the case of apoA-I. <i>Current Opinion in Investigational Drugs</i> , 2002, 3, 420-6.	2.3	10
57	Development of a lipid-rich, soft plaque in rabbits, monitored by histology and intravascular ultrasound. <i>Atherosclerosis</i> , 2001, 156, 277-287.	0.4	39
58	Increased Cholesterol Efflux Potential of Sera From ApoA-I Milano Carriers and Transgenic Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1257-1262.	1.1	114
59	Transgenic mice expressing a human apolipoprotein[a] allele. <i>Journal of Lipid Research</i> , 1999, 40, 994-1006.	2.0	18
60	Elevated triglycerides and low HDL cholesterol in transgenic mice expressing human apolipoprotein A-I-Milano. <i>Atherosclerosis</i> , 1998, 136, 139-146.	0.4	19
61	Human Apolipoproteins A-I and A-II in Cell Cholesterol Efflux. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 1417-1423.	1.1	45
62	A transgenic mouse model for the detection of cellular stress induced by toxic inorganic compounds. <i>Nature Biotechnology</i> , 1997, 15, 1392-1397.	9.4	41
63	Characterization of commercial antibodies for use in high resolution apo(a) phenotyping by immunoblot analysis. <i>Clinica Chimica Acta</i> , 1995, 240, 75-81.	0.5	5
64	Apo(a) Expression in Transgenic Mice. <i>Annals of the New York Academy of Sciences</i> , 1994, 714, 231-236.	1.8	0
65	Mechanisms of high-density lipoprotein reduction after probucol treatment: Changes in plasma cholesterol esterification/transfer and lipase-activities. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 229-235.	1.5	37
66	Sequence polymorphisms in the apolipoprotein (a) gene. Evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels. <i>Journal of Clinical Investigation</i> , 1993, 91, 1630-1636.	3.9	111
67	Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). <i>Journal of Clinical Investigation</i> , 1993, 92, 3029-3037.	3.9	227
68	Mechanisms of hdl reduction after probucol: Changes in cholesterol esterification/transfer and lipase activities. <i>Pharmacological Research</i> , 1992, 26, 30.	3.1	1
69	Activity profile of gemfibrozil on the major plasma lipoprotein parameters. <i>European Journal of Epidemiology</i> , 1992, 8, 120-124.	2.5	7
70	Atherogenesis in transgenic mice expressing human apolipoprotein(a). <i>Nature</i> , 1992, 360, 670-672.	13.7	279
71	Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. <i>Journal of Clinical Investigation</i> , 1992, 90, 52-60.	3.9	838
72	Management of lipoprotein-X accumulation in severe cholestasis by semi-selective LDL-apheresis. <i>American Journal of Medicine</i> , 1991, 90, 633-638.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients. European Journal of Clinical Investigation, 1991, 21, 384-388.	1.7	44
74	Predictability of low-density lipoprotein levels during apheretic treatment of hypercholesterolemia. European Journal of Clinical Investigation, 1991, 21, 209-214.	1.7	8
75	In vitro activity of probucol on cholesteryl ester transport. Lipids and Lipid Metabolism, 1990, 1045, 302-304.	2.6	8
76	Effects of probucol on the high density lipoprotein system in hypercholesterolaemic patients. Pharmacological Research, 1989, 21, 113-114.	3.1	2